AABB Standards for Cellular Therapy Services, Standard 5.24.1 addresses donor evaluation but not specifically the collection of autologous blood in the setting of bone marrow harvest. Given the important therapeutic implications of the collection and transfusion of autologous blood for bone marrow donor safety, these survey data highlight the variations in practice and gaps in knowledge, and further emphasize the need for written standard operating procedures and best practices to guide training, proficiency and optimal donor management.
The collection and transfusion of autologous blood in the management of healthy donors undergoing a bone marrow harvest has historically been an accepted standard of care. Given that the number of harvests may be increasing based on BMT-CTN 0201 data showing more chronic GvHD with peripheral blood as compared to bone marrow as the source of stem cells for unrelated donor transplantation, this practice is particularly relevant.
1 Autologous blood donation was recommended during the era of heightened concern over transfusion-transmitted infectious disease, and has been justified by the potentially large volume of blood loss associated with bone marrow harvesting. The World Marrow Donor Association (WMDA) and the National Marrow Donor Program (NMDP) have provided guidelines in the past for the collection of autologous blood based, in part, on the estimated blood loss or product total nucleated cell count anticipated for the collection procedure. [2] [3] [4] This practice, however, has recently become more controversial given that the risk:benefit ratio of pre-storage of autologous blood and indications for transfusion during or after the harvest have become less clear. Both the WMDA and NMDP have called this practice in to question, 4, 5 and the NMDP has recently left the decision about collection and transfusion of autologous blood to the discretion of the collection centers. In order to address this issue, the Product Collection and Clinical Practices Subsection of the AABB Cellular Therapies Section Coordinating Committee (CTSCC) formed an interorganizational working group, called the Bone Marrow Quality Improvement Initiative Working Group, that includes representatives from the Center for International Blood and Marrow Transplant Research (CIBMTR) Donor Health and Safety Committee, the American Society for Blood and Marrow Transplantation (ASBMT) and the NMDP. The initial charge to this group was to develop, distribute and analyze data from a survey regarding institutional policies and practices guiding autologous blood collection, storage and transfusion around bone marrow harvesting. This survey was developed and reviewed by the Working Group and validated in SurveyMonkey (San Mateo, CA, USA) (Supplementary Appendix 1 lists the survey questions). Characteristics of the survey respondents are described in Table 1 . Among the 120 US transplant centers contacted for this survey, 68 (57%) initiated the survey, including institutions that harvest marrow from pediatric and/or adult-related donors and centers that collect unrelated donor marrow for the NMDP. Interestingly, of the responding centers, 72% (39/54) and 64% (30/47) perform 10 or fewer bone marrow harvests per year from related adult and unrelated adults, respectively. Notable findings were that only half of the responding centers have a written policy guiding the collection and storage of autologous blood from related marrow donors. Most of these centers (70%, 33/47) follow NMDP guidelines regarding the number of autologous units collected and 59% (27/46) collect the maximum marrow volume per NMDP standards (20 mL/donor kg) from adult donors. Other questions addressed clinical practices such as the timing of autologous blood collection, when the donor's hemoglobin and/or hematocrit are assessed in relation to the harvest procedure, transfusion triggers, if and when iron supplementation is used and post-donation follow-up (Supplementary Appendix 2 provides additional responses). Three response domains are worthy of further mention:
1. About 23% (11/47) of centers do not collect any autologous blood from adult donors and among those that do, 42% (19/45) will collect blood within 3-7 days of the harvest. 2. Only 35% (16/46) of centers stated they have a written policy defining a threshold for post-operative transfusion of blood and 34% (13/38) and 41% (14/34) report they routinely transfuse autologous blood to adult-related and unrelated donors, respectively, regardless of post-operative hemoglobin level. 3. About 72% (33/46) of centers do not have a written policy to track and audit the use of blood transfusions for marrow donors.
This survey was not intended to address the efficacy or risk of autologous blood collection and transfusion for bone marrow donors. Previous analyses have suggested that donors who did not receive autologous blood have acceptable outcomes in terms of post-donation hemoglobin levels. 6, 7 As these were retrospective analyses, it is uncertain what criteria were used to transfuse or not transfuse the donors. In order to more fully explore the multiple donor and procedural variables that affect the collection and transfusion of autologous blood and the relationship of these variables to post-donation outcomes, our Bone Marrow Quality Improvement Initiative Working Group has proposed a large CIBMTR database review to formally evaluate these factors. Future investigations should include assessments of hemoglobin levels before and after blood storage (prior to marrow harvest) and complications from anemia after marrow harvest, post-operative hemoglobin levels in untransfused donors undergoing large volume harvests and clinical outcomes such as intra-and peri-operative hemodynamic status, the relative benefits of crystalloid solutions, colloid (for example, 5% albumin) and blood as replacement fluids, and post-donation symptoms that may be related to anemia such as orthostatic lightheadedness and syncope.
Potential biases in this analysis include the predominance of responding centers that perform o 10 harvests per year and the analysis of centers that responded vs those that did not. The survey nonetheless points out that one-quarter of centers do not collect autologous blood for bone marrow harvests. This could represent an emerging trend in the transplant community given the recent questions about this practice raised by the WMDA and the NMDP. The lack of written procedures for the collection and transfusion of blood and the tracking of those transfusions among a significant proportion of centers was a surprising finding. The Sixth Edition FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration does not address this specific need but does state that 'The Marrow Collection Facility shall establish and maintain policies and/or procedures addressing critical aspects of operation (Standard CM5.1).' Similarly, the Seventh Edition of
